The Oncology Institute, Inc. Common Stock
Here’s whether The Oncology Institute, Inc. Common Stock (TOI) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+6.40% over 10 days); strong 1-year return of +45.2%; 3-month momentum positive (+51.1%). Concerns: RSI 76 — overbought, elevated pullback risk. Currently 17.0% off its 52-week high. Score: +5/7.
TOI is in a confirmed uptrend, trading above both its 50-day ($3.15) and 200-day ($3.44) moving averages. With an RSI of 76.2, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +45.2% compares to +27.9% for SPY (beat the market by 17.3%).